Pharmacotherapeutic advances in the treatment of erectile dysfunction

Mayo Clinic Proceedings

Volumn 74, Issue 7, 1999, Pages 709-721

  Nehra, Ajay ^a   Barrett, David M ^a,b   Moreland, Robert B ^a  

^a MAYO CLINIC ROCHESTER   (United States)

^b BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; APOMORPHINE; CHLORPROMAZINE; CYCLIC AMP; DOPAMINE RECEPTOR STIMULATING AGENT; ENDOTHELIN RECEPTOR ANTAGONIST; FORSKOLIN; GLYCERYL TRINITRATE; INVICORP; PHENTOLAMINE; PHENTOLAMINE MESYLATE; PHOSPHODIESTERASE INHIBITOR; PRAZOSIN; PROSTAGLANDIN E1; PROSTAVASIN; SILDENAFIL; TRAZODONE; UNCLASSIFIED DRUG; VASOACTIVE INTESTINAL POLYPEPTIDE; YOHIMBINE;

DRUG DELIVERY SYSTEM; DRUG MECHANISM; ERECTILE DYSFUNCTION; HUMAN; INTRACAVERNOUS DRUG ADMINISTRATION; INTRAURETHRAL DRUG ADMINISTRATION; MALE; ORAL DRUG ADMINISTRATION; PATHOGENESIS; PATHOPHYSIOLOGY; REVIEW; SMOOTH MUSCLE RELAXATION; SUBLINGUAL DRUG ADMINISTRATION; TOPICAL DRUG ADMINISTRATION; TREATMENT PLANNING;

EID: 0032989330     PISSN: 00256196     EISSN: None     Source Type: Journal    
DOI: 10.4065/74.7.709     Document Type: Article

References (134)

1. Krane RJ, Goldstein I, Saenz de Tejada I. Impotence. N Engl J Med. 1989;321:1648-1659.
2. NIH Consensus Development Panel on Impotence. Impotence. JAMA. 1993;270:83-90.
3. Feldman HA, Goldstein I, Hatzichristou DG, Krane RJ, McKinlay JB. Impotence and its medical and psychosocial correlates: results of the Massachusetts Male Aging Study. J Urol. 1994;! 51:54-61.
4. Benêt AE, Melman A. The epidemiology of erectile dysfunction. Urol Clin North Am. 1995;22:699-709.
5. Jeremy JY, Mikhailidis DP. Cigarette smoking and erectile dysfunction. J R Soc Health. 1998;! 18:151-155.
6. Araujo AB, Durante R, Feldman HA, Goldstein I, McKinlay JB. The relationship between depressive symptoms and male erectile dysfunction: cross-sectional results from the Massachusetts Male Aging Study. PsychosomMed. 1998;60:458-465.
7. Laumann EO, Paik A, Rosen RC. Sexual dysfunction in the United States: prevalence and predictors. JAMA. 1999:281:537544.
8. Munarriz RM, Yan QR, Nehra A, Udelson D, Goldstein I. Blunt trauma: the pathophysiology of hemodynamic injury leading to erectile dysfunction. J Urol. 1995;153:1831-1840.
9. Meinhardt W, Kropman RF, Vermeij P, Nijeholt AA, Zwartendijk J. The influence of medication on erectile function. Int J Impôt Res. 1997;9:17-26.
10. Sharlip ID. Evaluation and nonsurgical management of erectile dysfunction. Urol Clin North Am. 1998;25:647-659.
11. Rosen R, Goldstein I, Heiman J, et al. The process of care model for evaluation and treatment of erectile dysfunction. Int J Impôt Res. 1999; 11:59-69.
12. Rosen RC, Riley A, Wagner G, Osterloh IH, Kirkpatrick J, Mishra A. The International Index of Erectile Function (IIEF): a multidimensional scale for assessment of erectile dysfunction. Urology. 1997 ;49:822-830.
13. Rosen RC. Sexual function assessment in the male: physiological and self-report measures. Int J Impôt Res. 1998;10(suppl 2):S59S63.
14. Porst H. Comparison of the International Index of Erectile Function (IIEF) with the diagnostic outcome in male impotence [abstract]. Int J Impôt Res. 1998;10(suppl 3):S67. Abstract 490.
15. Saenz de Tejada I. In the physiology of erection, signposts to impotence. Contemp Urol. 1992;7:52-68.
16. Andersson KE, Wagner G. Physiology of penile erection. Physiol Rev. 1995;75:191-236.
17. Christ GJ. The penis as a vascular organ: the importance of corporal smooth muscle tone in the control of erection. Urol Clin North Am. 1995;22:727-745.
18. Burnett AL. Nitric oxide in the penis: physiology and pathology. JUrol. 1997;157:320-324.
19. Lue TF, Dahiya R. Molecular biology of erectile function and dysfunction. Mol Urol. 1997; 1:55-64.
20. Moreland RB. Is there a role of hypoxema in penile fibrosis: a viewpoint presented to the Society for the Study of Impotence. Int J Impôt Res. 1998; 10:113-120.
21. Sattar AA, Salpigides G, Vanderhaeghen JJ, Schulman CC, Wespes E. Cavernous oxygen tension and smooth muscle fibers: relation and function. J Urol. 1995; 154:1736-1739.
22. Nehra A, Goldstein I, Pabby A, et al. Mechanisms of venous leakage: a prospective clinicopathological correlation of corporeal function and structure. J Urol. 1996;156:1320-1329.
23. Wespes E, Sattar AA, Golzarian J, Wery D, Daoud N, Schulman CC. Corporeal veno-occlusive dysfunction: predominantly intracavernous muscular pathology. J Urol. 1997;157:1678-1680.
24. Moreland RB, Gupta S, Goldstein I, Traish A. Cyclic AMP modulates TGF-,-induced fibrillar collagen synthesis in cultured human corpus cavernosum smooth muscle cells. Int J Impôt Res. 1998; 10:159-163.
25. Moreland RB, Watkins MT, Nehra A, et al. Oxygen tension modulates transforming growth factor-, expression and PGE production in human corpus cavernosum smooth muscle cells. Mo! Urol. 1998;2:41-47.
26. Mills TM, Reilly CM, Lewis RW. Androgens and penile erection: a review. J Androl. 1996;l?ié33-638.
27. Giuliano FA, Rampin O, Benoît G, Jardin A. Neural control of penile erection. Ural Clin North Am. 1995;22:747-766.
28. McKenna KE. Central control of penile erection. Int J Impôt Res. 1998;10(suppl 1):S25-S34.
29. Saenz de Tejada I, Moroukian P, Tessier J, Kim JJ, Goldstein I, Frohrib D. Trabecular smooth muscle modulates the capacitor function of the penis: studies on a rabbit model. Am J Physiol. 1991;260:H1590-H1595.
30. Udelson D, Nehra A, Hatzichristou DG, et al. Engineering analysis of penile hemodynamic and structural-dynamic relationships: part I-clinical implications of penile tissue mechanical properties. Int J Impôt Res. 1998;10:15-24.
31. Kirn N, Vardi Y, Padma-Nathan H, Daley J, Goldstein I, Saenz de Tejada I. Oxygen tension regulates the nitric oxide pathway: physiological role in penile erection. J Clin Invest. 1993;91:437-442.
32. Tarhan F, Kuyumcuoglu U, Kolsuz A, Özgül A, Cangüven Ö. Cavernous oxygen tension in the patients with erectile dysfunction. Int J Impôt Res. 1997;9:149-153.
33. Palmer LS, Valcic M, Melman A, Giraldi A, Wagner G, Christ GJ. Characterization of cyclic AMP accumulation in cultured human corpus cavernosum smooth muscle cells. J Urol. 1994;152:1308-1314.
34. Traish AM, Palmer MS, Goldstein l, Moreland RB. Expression of functional muscarinic acetylcholine receptor subtypes in human corpus cavernosum and in cultured smooth muscle cells. Receptor. 1995 ;5:159-176.
35. Stief CG, Noack T, Andersson KE. Signal transduction in cavernous smooth muscle. World J Urol. 1997;15:27-31.
36. Traish AM, Moreland RB, Gallant C, Huang YH, Goldstein I. Gprotein-coupled receptor agonists augment adenylyl cyclase activity induced by forskolin in human corpus cavernosum smooth muscle cells. Recept Signal Transduct. 1997;7:121 -132.
37. Kirn YC, Davies MG, Lee TH, Hagen PO, Carson CC III. Characterization and function of histamine receptors in corpus cavernosum. J Urol. 1995;153:506-510.
38. Traish AM, Moreland RB, Huang YH, Goldstein I. Expression of functional alpha2-adrenergic receptor subtypes in human corpus cavernosum and in cultured trabecular smooth muscle cells. Recept Signal Transduct. 1997;7:55-67.
39. Gupta S, Moreland RB, Yang S, Gallant CM, Goldstein I, Traish A. The expression of functional postsynaptic oc2-adrenoceptors in the corpus cavernosum smooth muscle. Br J Pharmacol. 1998;123:1237-1245.
40. Christ GJ. The "syncytial tissue triad": a model for understanding how gap junctions participate in the local control of penile erection. World J Urol. 1997; 15:36-44.
41. Diederichs W, Stief CG, Lue TF, Tanagho EA. Norepinephrine involvement in penile detumescence. J Urol. 1990; 143:12641266.
42. Reid K, Surridge DH, Morales A, et al. Double-blind trial of yohimbine in treatment of psychogenic impotence. Lancet. 1987; 2:421-423.
43. Riley AJ, Goodman RE, Kellett JM, Orr R. Double blind trial of yohimbine hydrochloride in the treatment of erection inadequacy. Sex Marital Ther. 1989;4:17-26.
44. Susset JG, Tessier CD, Wincze J, Bansal S, Malhotra C, Schwacha MG. Effect of yohimbine hydrochloride on erectile impotence: a double-blind study. J Urol. 1989;141:1360-1363.
45. Munoz M, Bancroft J, Turner M. Evaluating the effects of an alpha-2 adrenoceptor antagonist on erectile function in the human male, 1: the erectile response to erotic stimuli in volunteers. Psychopharmacology (Berl). 1994; 115:463-470.
46. Munoz M, Bancroft J, Beard M. Evaluating the effects of an alpha-2 adrenoceptor antagonist on erectile function in the human male, 2: the erectile response to erotic stimuli in men with erectile dysfunction, in relation to age and in comparison with normal volunteers. Psychopharmacology (Berl). 1994;! 15:471-477.
47. Morales A, Heaton JP, Johnston B, Adams M. Oral and topical treatment of erectile dysfunction: present and future. Urol Clin North Am. 1995;22:879-886.
48. Becker AJ, Stief CG, Machtens S, et al. Oral phentolamine as treatment for erectile dysfunction. J U ml. 1998:159:12141216.
49. Kaplan SA, Reis RB, Kohn IJ, Shabsigh R, Te AE. Combination therapy using oral apha-blockers and intracavernosal injection in men with erectile dysfunction. Urology. 1998;52:739-743.
50. Traish A, Gupta S, Gallant C, Huang YH, Goldstein I. Phentolamine mesylate relaxes penile corpus cavernosurn tissue by adrenergic and non-adrenergic mechanisms. Int J Impol Res. 1998:10:215-223.
51. Porst H. The rationale for prostaglandin E, in erectile failure: a survey of worldwide experience. J Urol. 1996:155:802-815.
52. Adams MA, Banting JD, Maurice DH, Morales A, Heaton JP. Vascular control mechanisms in penile erection: phytogeny and the inevitability of multiple and overlapping systems. Int J Impôt Res. 1997:9:85-91.
53. Melman A, Gingell JC. The epidemiology and pathophysiology of erectile dysfunction. J Urol. 1999:161:5-11.
54. Kloner RA, Jarow JP. Erectile dysfunction and sildenafil citrate and cardiologists [editorial]. AmJ Cardiol. 1999;83:576-582.
55. Moreland RB, Goldstein I, Kim NN, Traish A. Sildenafil citrate, a selective phosphodiesterase type 5 inhibitor: research and clinical implications in erectile dysfunction. Trends Endocrinol Metab. 1999:10:97-104.
56. Cahn D, Melman A, Valcic M, Christ GJ. Forskolin: a promising new adjunct to intracavernous pharmacotherapy. / Urol. 1996;155:1789-1794.
57. Mulhall JP, Daller M, Traish AM, et al. Intracavernosal forskolin: role in management of vasculogenic impotence resistant to standard 3-agent pharmacotherapy. J Urol. 1997;158:1752-1758.
58. Taher A, Meyer M, Stief CG, Jonas U, Forssmann WG. Cyclic nucleotide phosphodiesterase in human cavernous smooth muscle. World J Urol. 1997:15:32-35.
59. Rembold CM. Regulation of contraction and relaxation in arterial smooth muscle. Hypertension. 1992:20:129-137.
60. McMahon CG. A pilot study of the role of intracavernous injection of vasoactive intestinal peptide (VIP) and phentolamine mesylate in the treatment of erectile dysfunction. Int J Impôt Res. 1996;8:233-236.
61. Scharfstein JS, Keaney JF Jr, Slivka A, et al. In vivo transfer of nitric oxide between a plasma protein-bound reservoir and low molecular weight thiols. J Clin Invest. 1994:94:1432-1439.
62. Freedman JE, Frei B, Welch GN, Loscalzo J. Glutathione peroxidase potentiates the inhibition of platelet function by Snitrosothiols. J din Invest. 1995:96:394-400.
63. Welch GN, Upchurch GR Jr, Loscalzo J. Nitric oxide as a vascular modulator. Blood Rev. 1995;9:262-269.
64. Gupta S, Moreland RB, Munarriz R, Daley J, Goldstein I, Saenz de Tejada I. Possible role of Na-K-ATPase in the regulation of human corpus cavernosurn smooth muscle contractility by nitric oxide. BrJPharmacol. 1995;! 16:2201-2206.
65. Saenz de Tejada I, Cuevas P, Cuevas B, et al. S-nitrosylated alpha blockers as potential drugs for the treatment of impotence: biological activity of NMI-187 and NMI-227 [abstract], Int J Impôt Res. 1996:8:103. Abstract A16.
66. Boolell M, Allen MJ, Ballard SA, et al. Sildenafil: an orally active type 5 cyclic GMP-specific phosphodiesterase inhibitor for the treatment of penile erectile dysfunction. Int J Impôt Res. 1996;8:47-52.
67. Moreland RB, Goldstein I, Traish A. Sildenafil, a novel inhibitor of phosphodiesterase type 5 in human corpus cavernosurn smooth muscle cells. Life Sei. 1998;62:PL-309-PL-318.
68. Blanco R, Saenz de Tejada I, Goldstein I, Krane RJ, Wotiz HH, Cohen RA. Dysfunctional penile cholinergic nerves in diabetic impotent men. J Urol. 1990;144:278-280.
69. Saenz de Tejada I, Goldstein I, Azadzoi K, Krane RJ, Cohen RA. Impaired neurogenic and endothelium-mediated relaxation of penile smooth muscle from diabetic men with impotence. N Eng/ J Med. 1989:320:1025-1030.
70. Zippe CD, Kedia AW, Kedia K, Nelson DR, Agarwal A. Treatment of erectile dysfunction after radical prostatectomy with sildenafil citrate (Viagra). Urology. 1998:52:963-966.
71. Stief CG, Uckert S, Becker AJ, Truss MC, Jonas U. The effect of the specific phosphodiesterase (PDE) inhibitors on human and rabbit cavernous tissue in vitro and in vivo. J Urol. 1998; 159: 1390-1393.
72. Traish AM, Gupta S, Toselli P, Saenz de Tejada I, Goldstein I, Moreland RB. Identification of o-adrenergic receptor subtypes in human corpus cavemosum tissue and in cultured trabecular smooth muscle cells. Receptor. 1995;5:145-157.
73. Dausse J-P, Leriche A, Yablonsky F. Patterns of messenger RNA expression for o-adrenoceptor subtypes in human corpus cavernosum. J Urol. 1998; 160:597-600.
74. Gwinup G. Oral phentolamine in nonspecific erectile insufficiency. Ann Intern Med. 1988;109:162-163.
75. Zorgniotti AW. Experience with buccal phentolamine mesylate for impotence. Int J Impôt Res. 1994;6:37-41.
76. Junemann K-P, Alken P. Pharmacotherapy of erectile dysfunction: a review. Int J Impôt Res. 1989; 1:71-93.
77. Grimm RH Jr, Grandits GA, Prineas RJ, et al, TOMHS Research Group. Long-term effects on sexual function of five antihypertensive drugs and nutritional hygienic treatment in hypertensive men and women: Treatment of Mild Hypertension Study (TOMHS). Hypertension. 1997;29:8-14.
78. Braga RS, Braga LTCM. Chlorpromazine: a good drug substitute for phentolamine; a follow up study of 174 patients [abstract]. Int J Impôt Res. 1996;8:113. Abstract A56.
79. Kulkarni VR, Shah RS, Gupte DM, Mehta MK. A clinical study of the erection-inducing effects of intra-cavernosal chlorpromazine [abstract]. Int J Impôt Res. 1996;8:143. Abstract D83.
80. Marquer C, Bressolle F. Moxisylyte: a review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic use in impotence. Fundam Clin Pharmacol. 1998;12:377-387.
81. Ozkara H, Alici B, Akkus E, Hattat H. Prazosin as medical treatment option for impotent patients without organic erectile dysfunction [abstract]. Int J Impôt Res. 1996;8:150. Abstract D112.
82. Teloken C, Rhoden EL, Sogari P, Dambros M, Souto CA. Therapeutic effects of high dose yohimbine hydrochloride on organic erectile dysfunction. / Urol. 1998;159:122-124.
83. Gupta S, Daley J, Goldstein I, Traish AM. Lack of selectivity of agents for alpha-adrenergic receptors in human corpus cavernosum [abstract]. Int J Impôt Res. 1996;8:105. Abstract A25.
84. Azadzoi KM, Payton T, Krane RJ, Goldstein I. Effects of intracavernosal trazodone hydrochloride: animal and human studies. J Urol. 1990; 144:1277-1282.
85. Saenz de Tejada I, Ware JC, Blanco R, et al. Pathophysiology of prolonged penile erection associated with trazodone use. J Urol. 1991;l45:60-64.
86. Meinhardt W, Schmilz PI, Kropman RF, de la Fuente RB, Lycklama a Nijeholt AA, Zwartendijk J. Trazodone, a double blind trial for treatment of erectile dysfunction. Int J Impôt Res. 1997;9:163-165.
87. Heaton JPW, Adams MA, Morales A, et al. Apomorphine SL is effective in the treatment of non-organic erectile dysfunction: results of a multicenter trial [abstract]. Int J Impôt Res. 1996;8:115. Abstract A64.
88. Padma-Nathan H, Fromm S, Ruff DD, Rosen RC, McMurray JG. Efficacy and safety of Apomorphine SL vs placebo for male erectile dysfunction (MED) [abstract], Int J Impôt Res. 1998;10(suppl 3):S57. Abstract 419.
89. Adams JA, Banting JD, Manabe K, Morales A, Heaton JPW. The major role for nitric oxide in the penis is to regulate the vasoconstrictor actions of endothelins [abstract]. Int J Impôt Res. 1996;8:124. Abstract D07.
90. Whittingham HA, Banting JD, Manabe K, Morales A, Adams MA, Heaton JPW. Erectile dysfunction induced acute NO synthase blockade is reversed by an endothelin receptor antagonist [abstract]. Int J Impôt Res. 1996;8:100. Abstract A06.
91. Hatzichristou DG, Saenz de Tejada I, Kupferman S, et al. In vivo assessment of trabecular smooth muscle tone, its application in pharmaco-cavernosometry and analysis of intracavernosal pressure determinants. J Urol. 1995;153:1126-1135.
92. Moreland RB, Traish A, McMillin MA, Smith B, Goldstein I, Saenz de Tejada I. PGE, suppresses the induction of collagen synthesis by transforming growth factor-, in human corpus cavernosum smooth muscle. J Urol. 1995;153:826-834.
93. Ul-Hasan M, El-Sakka AI, Lee C, Yen T-SB, Dahiya R, Lue TF. Expression of TGF-1 mRNA and ultrastructural alterations in pharmacologically induced prolonged penile erection in a canine model.,/ Urol. 1998; 160:2263-2266.
94. Fisher C, Gorss J. Zuch J. Cycle of penile erection synchronous with dreaming (REM) sleep: preliminary report. Arch Gen Psychiatrv. 1965:12:29-45.
95. Karacan I, Williams RL, Thornby JI, Salis PJ. Sleep-related penile tumescence as a function of age. Am J Psychiatry. 1975; 132:932-937.
96. Fallon B. Intracavernous injection therapy for male erectile dysfunction. Urn! Clin North Am. 1995;22:833-845.
97. Linet OI, Ogrinc FG, Alprostadil Study Group. Efficacy and safety of intracavernosal alprostadil in men with erectile dysfunction. N EnglJMed. 1996;334:873-877.
98. Buvat J, Costa P, Morlier D, Lecocq B, Stegmann B, Albrecht D. Double-blind multicenter study comparing alprostadil alphacyclodextrin with moxisylyte chlorhydrate in patients with chronic erectile dysfunction. J Urol. 1998;159:116-119.
99. Hellstrom WJ, Bennett AH, Gesundheit N, et al. A double-blind, placebo-controlled evaluation of the erectile response to transurethral alprostadil. Urology. 1996:48:851-856.
100. Padma-Nathan H, Hellstrom WJG, Kaiser FE, et al, Medicated Urethra! System for Erection (MUSE) Study Group. Treatment of men with erectile dysfunction with transurethral alprostadil. N EnglJ Med. 1997:336:1-7.
101. Lewis RW, Weldon K, Nemo K. Combined use of transurethral alprostadil and an adjustable penile constriction band in men with erectile dysfunction: results from a multicenter trial [abstract]. Int J Impôt Res. 1998;10(suppl 3):S49. Abstract 365.
102. Porst H. Transurethral alprostadil with MUSE (Medicated Urethral System for Erection) vs intracavernous alprostadil-a comparative study in 103 patients with erectile dysfunction. Int J ImpotRes. 1997:9:187-192.
103. WerthmanP, RajferJ. MUSE therapy: preliminary clinical observations. Urology. 1997:50:809-811.
104. Fulgham PF, Cochran JS, Denman JL, et al. Disappointing initial results with transurethral alprostadil for erectile dysfunction in a urology practice setting. J Urol. 1998:160:2041-2046.
105. Peterson CA, Bennett AH, Hellstrom WJ, et al. Erectile response to transurethral alprostadil, prazosin and alprostadil-prazosin combinations. J Urol. 1998; 159:1523-1527.
106. Dugan JA, Hildebrand KR, Lawson GM, Nehra A, Bostwick DG, Barrel! DM. A new transurethral drug delivery system for erectile dysfunction: iontophoresis [abstract]. Int J Impôt Res. 1996:8:200. Abstract P68.
107. Kirn ED, el-Rashidy R. Me Vary KT. Papaverine topical gel for treatment of erectile dysfunction. J Urol. 1995;153:361-365.
108. Kim ED, McVary KT. Topical prostaglandin-E, for the treatment of erectile dysfunction. J Urol. 1995:153:1828-1830.
109. Goldstein I. Padma-Nathan H, Pelham R, Riggi S. Safety and efficacy of topical alprostadil gel formulation (Topiglan) in the treatment of erectile dysfunction [abstract]. Int J Impôt Res. 1998:l()(suppl 3):S58. Abstract 428.
110. Gramkow J, Lendorf A. Zhu J, Meyhoff HH. Transcutaneous nitroglycerine in the treatment of erectile dysfunction: a placebo controlled clinical trial. Int J Impôt Res. 1999; 11:35-39.
111. Sato Y. Horita H. Adachi H, et al. Effect of oral administration of prostaglandin El on erectile dysfunction. Br J Urol. 1997;80: 772-775.
112. Derry FA. Dinsmore WW, Fraser M, et al. Efficacy and safety of oral sildenafil (Viagra) in men with erectile dysfunction caused by spinal cord injury. Neurolog\. 1998:51:1629-1633.
113. Goldstein I. Lue TF, Padma-Nathan H, Rosen RC, Steers WD, Wicker PA. Sildenafil Study Group. Oral sildenafil in the treat-
114. ment of erectile dysfunction. N Engl J Med. 1998:338:13971404.
115. Steers WD, Sildenafil Study Group. Meta-analysis of the efficacy of sildenafil (Viagra) in the treatment of severe erectile dysfunction [abstract]. J Urol. 1998;159(suppl):238. Abstract 910.
116. Cheitlin MD, Hutter AM Jr, Brindis RG, et al. Use of sildenafil (Viagra) in patients with cardiovascular disease [ACC/AHA Expert Consensus Document]. J Am Coll Cardiol. 1999;33:273-282.
117. Conti CR, Pepine CJ, Sweeney M. Efficacy and safety of sildenafil citrate in the treatment of erectile dysfunction in patients with ischémie heart disease. Am J Cardiol. 1999;83:29C34C.
118. Marks LS, Duda C, Dorey FJ, Macairan ML, Santos PB. Treatment of erectile dysfunction with sildenafil. Urology. 1999;53: 19-24.
119. Maytom MC, Deny FA, Dinsmore WW, et al. A two-part study of sildenafil (Viagra) in men with erectile dysfunction caused by spinal cord injury. Spinal Cord. 1999;37:110-116.
120. Rendell MS, Rajfer J, Wicker PA, Smith MD, Sildenafil Diabetes Study Group. Sildenafil for treatment of erectile dysfunction in men with diabetes: a randomized controlled trial. JAMA. 1999; 281:421-426.
121. Chew KK, Stuckey BG, Earle CM, Dhaliwal SS, Keogh EJ. Penile fibrosis in intracavernosal prostaglandin El injection therapy for erectile dysfunction. IntJ Impôt Res. 1997:9:225-229.
122. Cawello W, Schweer H, Dietrich B, et al. Pharmacokinetics of prostaglandin Et and its main metabolites after intracavernous injection and short-term infusion of prostaglandin E, in patients with erectile dysfunction. J Urol. 1997;158:1403-1407.
123. Earle CM, Chew KK, Stuckey EGA, Keogh EJ. Pain with intracavernosal therapy [abstract]. Int J Impôt Res. 1996;8:114. Abstract A62.
124. Sato Y, Suzuki N, Adachi H, Hisasue S, Horita H, Tukamoto T. Effect of neurotropin for penile pain induced by intracavernous injection of prostaglandin E, [abstract]. Int J Impôt Res. 1996:8:139. Abstract D67.
125. Montorsi F, Guazzoni G, Strambi LF, et al. Recovery of spontaneous erectile function after nerve-sparing radical retropubic prostatectomy with and without early intracavernous injections of alprostadil: results of a prospective, randomized trial. / Urol. 1997:158:1408-1410.
126. Dinsmore WW, Alderdice DK. Vasoactive intestinal polypeptide and phentolamine mesylate administered by autoinjector in the treatment of patients with erectile dysfunction resistant to other intracavernosal agents. Br J Urol. 1998:81:437-440.
127. Cooper JD, Muirhead DC, Taylor JE, Baker PR. Development of an assay for simultaneous determination of sildenafil (Viagra) and its metabolite (UK-103,320) using automated sequential trace enrichment of dialysates and high-performance liquid chromatography. J Chromatogr B Biomed Sei Appl. 1997:701:87-95.
128. Balon R. Fluvoxamine-induced erectile dysfunction responding to sildenafil. J Sex Marital Ther. 1998;24:313-317.
129. Schaller JL, Behar D. Sildenafil citrate for SSRI-induced sexual side effects [letter]. AmJ Psychiatry. 1999:156:156-157.
130. Rosenberg KP. Sildenafil citrate for SSRI-induced sexual side effects [letter]. Am J Psychiatry. 1999; 156:157.
131. Morales A, Gingell C, Collins M, Wicker PA, Osterloh 1H. Clinical safety of oral sildenafil citrate (Viagra) in the treatment of erectile dysfunction. Int J Impôt Res. 1998:10:69-73.
132. Ballard SA, Gingell CJ, Tang K, Turner LA, Price ME, Naylor AM. Effects of sildenafil on the relaxation of human corpus cavernosum tissue in vitro and on the activities of cyclic nucleotide phosphodiesterase isozymes. / Urol. 1998; 159:2164-2171.
133. Fox DA, Campbell ML, Blocker YS. Functional alterations and apoptotic cell death in the retina following developmental or adult lead exposure. Neurotoxicology. 1997:18:645-664.
134. Donahue SP, Taylor RJ. Pupil-sparing third nerve palsy associated with sildenafil citrate (Viagra). Am J Ophthalmol. 1998; 126: 476-477.